Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7355933 | 0.85 | ROCK1 (0.46) | ROCK1ALDH1A1L3MBTL1ADORA3TMIGD3 | |
| SCHEMBL17321402 | 0.83 | ROCK1 (0.43) | ROCK1ALDH1A1L3MBTL1ADORA3TMIGD3 | |
| SCHEMBL19997306 | 0.83 | ROCK1 (0.43) | ROCK1ALDH1A1L3MBTL1ADORA3TMIGD3 | |
| SCHEMBL14605053 | 0.83 | ROCK1 (0.45) | ROCK1ALDH1A1TMIGD3KDM4EHPGD | |
| SCHEMBL6934846 | 0.80 | KDM4E (0.56) | ROCK1ALDH1A1KDM4EHPGD | |
| SCHEMBL2179459 | 0.74 | L3MBTL1 (0.41) | ROCK1ALDH1A1L3MBTL1KDM4EHPGD | |
| Bromide SCHEMBL17873904 | 0.73 | L3MBTL1 (0.40) | ROCK1ALDH1A1L3MBTL1KDM4EHPGD | |
| SCHEMBL20595996 | 0.72 | KDM4E (0.43) | ALDH1A1L3MBTL1KDM4EHPGDMAPT | |
| SCHEMBL16283544 | 0.72 | PDE10A (0.49) | — | |
| SCHEMBL14644414 | 0.71 | ROCK1 (0.35) | ROCK1ALDH1A1L3MBTL1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | ROCK1 3/4885ALDH1A1 2590/4885L3MBTL1 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.